Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B round.

Pharmaceutical giant GlaxoSmithKline is sidestepping its pledge to lower asthma inhaler prices, a key senator charged Wednesday, in the latest effort by Democrats to pressure drug companies on the ...

India's GlaxoSmithKline Pharma reports higher profit on strong demand for respiratory drugs India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday ...

The first designs have been released of the housing-led redevelopment of GlaxoSmithKline’s former west London HQ, drawn up by ...

At GlaxoSmithKline, we never lose sight of the fact that patients are at the core of what we do and that millions of lives are impacted by cancer. The patient’s voice is at the heart of our ...

The global nicotine gums and mints market is projected to reach approximately USD 1,536.2 million by the end of 2024, with a ...

DUBLIN--(BUSINESS WIRE)--The "Enterprise Tech Ecosystem Series: GSK plc 2024" company profile has been added to ResearchAndMarkets.com's offering. The report provides insights into company's tech ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

Commenting on the results, Bhushan Akshikar, MD of GlaxoSmithKline Pharmaceuticals, highlighted the company’s strategic initiatives in strengthening its market presence and enhancing access to ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the BSE.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...